ADVERTISEMENT
2 /3 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Business

CordenPharma, GE form oligonucleotide services pact

by Rick Mullin
July 17, 2017 | APPEARED IN VOLUME 95, ISSUE 29

CordenPharma International and GE Healthcare’s Dharmacon division are joining to provide what they call an end-to-end service for oligonucleotide-based drug discovery. The GE unit offers custom synthesis of complex oligos to support research. CordenPharma provides larger-scale oligos manufacturing, a service it launched last year after investing in a Boulder, Colo., plant it acquired from Roche in 2011. CordenPharma currently supports early-stage clinical development and expects to begin commercial-scale manufacturing by the end of the year.

X

Article:

This article has been sent to the following recipient:

Leave A Comment

*Required to comment